新股消息 | 江西生物港股IPO招股书失效

Core Viewpoint - Jiangxi Biological is the largest provider of human TAT (tetanus antitoxin) in China and globally, with significant market shares projected for 2024 [1] Company Summary - Jiangxi Biological submitted its Hong Kong IPO prospectus on April 11, which became invalid after six months on October 11 [1] - The joint sponsors for the IPO are CICC and China Merchants Securities International [1] Industry Summary - According to Frost & Sullivan, Jiangxi Biological holds a market share of 65.8% in China and 36.6% globally for human TAT based on projected sales in 2024 [1] - Tetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing the toxins produced by the tetanus bacteria, thus preventing and treating tetanus infections [1]